Investigating undruggable targets in cancer research Blog Post

[…] decades and the term is becoming increasingly inaccurate. A few so-called undruggable targets, such as Bcl-2 and RAS, have been successfully targeted with clinically approved inhibitors. Therefore, “difficult to drug” […]

Anti-BCL2 [bcl-2/90] Product

Damage to the Bcl-2 gene has been identified as a cause of a number of cancers, including melanoma, breast, prostate, chronic lymphocytic leukemia, and lung cancer, and a possible cause […]

Anti-BCL2 [bcl-2/124] Product

Monoclonal antibody which binds anti-apoptotic regulator BCL2, used to aid in differentiating between various lymphomas and as prognostic biomarker in various cancers.

30 micrograms of detergent extracts of the indicated cell lines were loaded on a 12.5 SDS PAGE and ECL stained using SG36 as primary antibody against Praf2 diluted 1

Anti-PRAF2 [SG36] Product

Praf2 is a novel protein involved in endoplasmic reticulum to golgi transport. It has been found up-regulated in several cancers and it has been found to interact with Bcl-xL/Bcl-2

Anti-BCLAF1 [BCLAF1] Product

[…] the nucleus and the cytoplasm. Overexpression of BCLAF1 promotes apoptosis by preventing the transcription of Bcl-2. Bcl-2 is one of many key regulators of apoptosis which are essential for development, […]

Anti-PD-L1 [29E.2A3] Product

[…] lymph nodes through apoptosis which is further mediated by a lower regulation of the gene Bcl-2. PD-L1 binds to its receptor, PD-1, found on activated T cells, B cells, and […]